Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE-02: Sacituzumab Govitecan Combinations in First-line NSCLC
NCT05186974Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started May 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05186974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186974.